{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:24:25Z","timestamp":1780622665312,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Journal Armed Forces India"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.mjafi.2016.12.003","type":"journal-article","created":{"date-parts":[[2017,1,7]],"date-time":"2017-01-07T10:38:08Z","timestamp":1483785488000},"page":"12-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antitubercular therapy induced liver function tests abnormalities in human immunodeficiency virus infected individuals"],"prefix":"10.1016","volume":"73","author":[{"given":"Pankaj","family":"Puri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navjyot","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Pathania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.K.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.K.","family":"Sashindran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mjafi.2016.12.003_bib0180","article-title":"Tuberculosis and HIV","author":"Luetkemeyer","year":"2013","journal-title":"HIV In Site"},{"issue":"17","key":"10.1016\/j.mjafi.2016.12.003_bib0185","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1097\/01.aids.0000189864.90053.22","article-title":"Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984\u20132004","volume":"19","author":"Schneider","year":"2005","journal-title":"AIDS"},{"issue":"13","key":"10.1016\/j.mjafi.2016.12.003_bib0190","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mjafi.2016.12.003_bib0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","article-title":"Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study","volume":"43","author":"Palella","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.mjafi.2016.12.003_bib0200","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00126334-200312010-00004","article-title":"Grade 4 events are as important as AIDS events in the era of HAART","volume":"34","author":"Reisler","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"suppl 2","key":"10.1016\/j.mjafi.2016.12.003_bib0205","first-page":"S24","article-title":"Hepatic safety and HAART","volume":"3","author":"McGovern","year":"2004","journal-title":"J Int Assoc Phys AIDS Care (Chic)"},{"issue":"1","key":"10.1016\/j.mjafi.2016.12.003_bib0210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of Hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mjafi.2016.12.003_bib0215","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1545109708330906","article-title":"HIV-related liver disease: ARV drugs, coinfection, and other risk factors","volume":"8","author":"Puoti","year":"2009","journal-title":"J Int Assoc Phys AIDS Care (Chic)"},{"issue":"10","key":"10.1016\/j.mjafi.2016.12.003_bib0220","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/QAD.0b013e32814e6b08","article-title":"Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and Hepatitis B","volume":"21","author":"Hoffman","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.mjafi.2016.12.003_bib0225","first-page":"536","article-title":"Joint Tuberculosis Committee of the British Thoracic Society Chemotherapy and management of tuberculosis in the United Kingdom","volume":"53","year":"1998","journal-title":"Thorax"},{"key":"10.1016\/j.mjafi.2016.12.003_bib0230","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.mjafi.2016.12.003_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.mjafi.2016.12.003_bib0240","series-title":"Global Tuberculosis Control","year":"2014"},{"issue":"6","key":"10.1016\/j.mjafi.2016.12.003_bib0245","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"May (5)","key":"10.1016\/j.mjafi.2016.12.003_bib0250","doi-asserted-by":"crossref","first-page":"e5561","DOI":"10.1371\/journal.pone.0005561","article-title":"Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review","volume":"4","author":"Suchindran","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.mjafi.2016.12.003_bib0255","series-title":"Implementing the WHO Stop TB Strategy: A Handbook for National Tuberculosis Control Programmes","first-page":"67","year":"2008"},{"issue":"suppl 3","key":"10.1016\/j.mjafi.2016.12.003_bib0260","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1086\/651475","article-title":"Synergistic pandemics: confronting the global HIV and tuberculosis epidemics","volume":"50","author":"Mayer","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.mjafi.2016.12.003_bib0265","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4102\/sajhivmed.v14i3.63","article-title":"Consensus statement: management of drug-induced liver injury in HIV-positive patients treated for TB","volume":"14","author":"Jong","year":"2013","journal-title":"SA J HIV Med"},{"issue":"2","key":"10.1016\/j.mjafi.2016.12.003_bib0270","first-page":"229","article-title":"Adverse effects of antiretroviral therapy for HIV infection","volume":"170","author":"Montessori","year":"2004","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.mjafi.2016.12.003_bib0275","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"Breen","year":"2006","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.mjafi.2016.12.003_bib0280","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1258\/ijsa.2008.008361","article-title":"Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs","volume":"20","author":"Marks","year":"2009","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.mjafi.2016.12.003_bib0285","series-title":"Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach 2010 Revision","year":"2010"},{"key":"10.1016\/j.mjafi.2016.12.003_bib0290","series-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: What's New","year":"2015"},{"key":"10.1016\/j.mjafi.2016.12.003_bib0295","series-title":"European AIDS Clinical Society Guidelines Version 8.0","year":"2015"},{"issue":"suppl 2","key":"10.1016\/j.mjafi.2016.12.003_bib0300","first-page":"S8","article-title":"Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors","volume":"38","author":"Dieterich","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mjafi.2016.12.003_bib0305","first-page":"729","article-title":"Liver damage in HIV-infected patients","volume":"7","author":"Wnuk","year":"2001","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.mjafi.2016.12.003_bib0310","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.23716","article-title":"Clinical syndromes and consequences of antiretroviral related hepatotoxicity","volume":"52","author":"Nunez","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.mjafi.2016.12.003_bib0315","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clinre.2013.02.008","article-title":"Hepatoxicity of new antiretrovirals: a systematic review","volume":"37","author":"Surgers","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"10.1016\/j.mjafi.2016.12.003_bib0320","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1545109711401411","article-title":"Higher risk of severe drug-induced liver injury among Hispanic HIV-infected patients after initiation of highly active antiretroviral therapy","volume":"10","author":"Lamar","year":"2011","journal-title":"J Int Assoc Phys AIDS Care (Chic)"},{"key":"10.1016\/j.mjafi.2016.12.003_bib0325","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1086\/649922","article-title":"Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV infected persons without Hepatitis B or C virus coinfection","volume":"50","author":"Kovari","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.mjafi.2016.12.003_bib0330","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1473-3099(07)70262-1","article-title":"Is it safe to switch between efavirenz and nevirapine in the event of toxicity?","volume":"7","author":"Mehta","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"suppl 2","key":"10.1016\/j.mjafi.2016.12.003_bib0335","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1086\/381444","article-title":"Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors","volume":"38","author":"Sulkowski","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.mjafi.2016.12.003_bib0340","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/infdis\/171.5.1295","article-title":"Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS related Pneumocystis carinii pneumonia","volume":"171","author":"Hughes","year":"1995","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.mjafi.2016.12.003_bib0345","first-page":"410","article-title":"A practical approach to the diagnosis and management of paradoxical tuberculosis immune reconstitution inflammatory syndrome","volume":"29","author":"Meintjes","year":"2011","journal-title":"Contin Med Educ"},{"issue":"6","key":"10.1016\/j.mjafi.2016.12.003_bib0350","doi-asserted-by":"crossref","first-page":"506","DOI":"10.7196\/SAMJ.5650","article-title":"Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa","volume":"102","author":"Schutz","year":"2012","journal-title":"S Afr Med J"}],"container-title":["Medical Journal Armed Forces India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123716301976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123716301976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:44:01Z","timestamp":1759837441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0377123716301976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0377123716301976"],"URL":"https:\/\/doi.org\/10.1016\/j.mjafi.2016.12.003","relation":{},"ISSN":["0377-1237"],"issn-type":[{"value":"0377-1237","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitubercular therapy induced liver function tests abnormalities in human immunodeficiency virus infected individuals","name":"articletitle","label":"Article Title"},{"value":"Medical Journal Armed Forces India","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mjafi.2016.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V. on behalf of Director General, Armed Forces Medical Services.","name":"copyright","label":"Copyright"}]}}